CEO and Chairman at CRISPR Therapeutics @CRISPRTX, which is pioneering a new era of gene-based medicines. Tweets are my own.
Joined October 2015
- Tweets 262
- Following 284
- Followers 4,651
- Likes 105
Photos and videos
Samarth Kulkarni retweeted
Jun 12
$VRTX $CRSP: New CASGEVY paediatric data looks strong. In ages 5–11, 11 SCD patients dosed; 8/8 evaluable were VOC-free ≥12 months. In TDT, 15 dosed; 8/8 evaluable achieved transfusion independence ≥12 months. US review underway; UK & Saudi submissions completed. Increases TAM
5
17
1,869
Samarth Kulkarni retweeted
Apr 20
I am extremely skeptical of the long-term prospects for in vivo gene therapy with viral vectors that do random or semi-random integration.
15
8
153
26,569
Apr 19
Congrats to Kathy High and Stu Orkin (and their colleagues) on winning the Breakthrough Prize, both of whom I’ve had the pleasure of working closely with! Luxturna and Casgevy are groundbreaking therapies that will pave the way for many more.
2
14
1,479
Samarth Kulkarni retweeted
Centessa has entered a definitive agreement to be acquired by @EliLillyandCo. To our team, investigators, patients, and advocates: thank you!
Please refer to today’s full announcement for key information and cautionary statements: investors.centessa.com/news-…
4
17
47
16,631
22 Dec 2025
Today we shared an update on zugo-cel (formerly CTX112) - best-in-class allogeneic CD19 CART! The data reflect encouraging progress across autoimmune disease and hematologic malignancies and support the continued advancement of zugo-cel across multiple disease settings. @CRISPRTX
22 Dec 2025
Today, we shared a clinical update on zugo-cel (formerly known as CTX112™), reflecting continued progress across autoimmune disease and hematologic malignancies. Learn more here: bit.ly/4asQ0ub
6
5
34
5,446
8 Nov 2025
#AHA25 and @NEJM data for CTX310 by @ProfSNicholls . A single in vivo administration safely and durably lowered ANGPTL3, reducing triglycerides and LDL, progress toward applying gene editing to more common diseases. @CRISPRTX
6
8
44
4,004
15 Oct 2025
Enjoyed this discussion with @Nimish1316 on the gene editing space and the biotech sector at large! I've gotten a chance to work closely with Nimish on Oruka Tx
🎙On our latest episode of Running Through Walls, @Nimish1316 speaks with @CRISPRTX CEO & Chairman @CrisprSam about their incredible gene-editing platform and his advice for building businesses around life-changing science. Listen more here: bit.ly/4n8iZGf
1
6
1,518
20 Sep 2025
Fully agree with Bob
20 Sep 2025
USA message should be “We want the best and brightest scientists and their families to come here. And stay here. And innovate here.” Getting our ass kicked by our adversaries in drones and robots and AI is not a fun option.
1
1
5
1,620
Samarth Kulkarni retweeted
12 Sep 2025
Thank you, @Shea_ARK, for surfacing the potential value of one of the most important biology breakthroughs of our time: CRISPR gene editing. Many analysts seem to think that one-time cures will not be a good business, @ARK Invest begs to differ! $CRSP, $NTLA, $BEAM, $PRME
11 Sep 2025
Cardiovascular disease is the world’s leading killer. With CRISPR-based therapies targeting lipid metabolism genes, a one-time treatment could reshape prevention and open a ~$2.8T market. Read @Shea_ARK's analysis in her first ARK research paper.
ark-invest.com/articles/anal…
75
46
412
204,772
Samarth Kulkarni retweeted
10 Sep 2025
👀 shot > pill?
💉 > 💊 at a certain point
@bioinvestor24 cites an $ABBV survey that shows psoriasis pts prefer a q3m injection over a daily pill.
Analysts often assume “oral = convenient” for $KYMR in AD vs $APGE q3m shot. Reality is efficacy freedom from daily dosing often trumps pill convenience.
At a certain point efficacy is NOT perceived as equal, where that standard deviation lies varies, but end of day patients want what works, not what’s easy.
10 Sep 2025
5
3
26
10,606
Samarth Kulkarni retweeted
3 Aug 2025
Lp(a) and me.
I share my story here to raise awareness about elevated Lp(a) … 20% of US adults have elevated levels of lipoprotein(a).
Know your number #cmgsays washingtonpost.com/health/20…
9
20
75
8,073
28 Jun 2025
Thank you! It’s a reflection of all the employees who are dedicated to the cause of bringing cures to patients!
28 Jun 2025
Congrats to @CrisprSam - the CEO of @CRISPRTX on being part of the TIME100’s Health list - honoring the 100 most influential people in health today. $CRSP is the first-ever company to receive an FDA approval for its Gene Editing treatment - CASGEVY. A well-deserved recognition!
ALT Congratulations to CrisprSam - the CEO of CRISPR Therapeutics on being part of the TIME100Health list — honoring the 100 most influential people in health today. CRISPR therapeutics wass the first-ever company to receive an FDA approval for its CASGEVY Gene Editing treatment. A well-deserved recognition!
14
1
34
4,243
27 Jun 2025
Congrats @CRISPRTX on being named to the @TIME Most Influential Companies of 2025 list! Proud of the full company and excited for the future of genetic medicine. #CRISPRTX #TIME100Companies
Introducing TIME's most influential companies of 2025: 100 companies around the world that shaped culture, made new strides, reached milestones, and more ti.me/3TIvR9G
3
1
32
3,376
20 May 2025
We are excited to announce our collaboration with Sirius Tx. This strategic partnership expands our therapeutic toolkit & broadens our cardiovascular portfolio. We look forward to working closely with the Sirius team to advance this exciting asset
19 May 2025
Today, we announced a collaboration with Sirius Tx to co-develop SRSD107, a next generation, long-acting Factor XI siRNA for the treatment of thromboembolic disorders. This will expand our cardiovascular portfolio and broaden our therapeutic toolkit. bit.ly/4kjPEaS
ALT "We are excited to partner with Sirius, and broaden our cardiovascular medicine portfolio, on the heels of promising top-line data that we recently shared for CTX310, which targets ANGPTL3. Coagulation Factor XI represents an innovative and highly compelling target for treating thrombotic diseases that affect millions worldwide. SRSD107, which targets Factor XI, has the potential to be a best-in-class therapy, offering infrequent dosing and improved patient outcomes. Sirius’ siRNA platform complements our existing capabilities and expands our therapeutic toolkit, enabling us to develop a broader range of transformative gene-based medicines." - Dr. Samarth Kulkarni, CEO & Chairman, CRISPR Therapeutics (included headshot) 5/19/25 Press release: CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies
6
1
38
3,762
8 May 2025
Thank you @TIME for naming me on the #TIME100HEALTH list! Honored to be included and congrats to all the 2025 honorees. time.com/time100health
TIME's new cover: Meet this year's #TIME100Health, a community of leaders—scientists, doctors, advocates, educators, and policy-makers, among others—who are changing the health of the world. ti.me/43802LZ
5
1
15
1,877
6 May 2025
Proud to share our latest business updates and positive top-line results from our Phase 1 clinical trial of CTX310 targeting ANGPTL3. Congratulations to our team and all who contributed to this milestone! @CRISPRTX
7
4
64
5,532
Samarth Kulkarni retweeted
8 Apr 2025
U.S. leadership in biotech is a national security, economic, and public health imperative.
With the attack on science and universities, instability at FDA, & weakening of the capital markets, we are at grave risk of ceding this leadership to China.
This must not happen!
8 Apr 2025
The U.S. has long led the world in biotech—driving innovation, saving lives, and fueling our economy and national security. But that leadership is now at risk. @biotech_gov report makes it clear: without bold action, we risk falling behind.
Read more: bio.org/press-release/bio-st…
7
13
78
8,926
Samarth Kulkarni retweeted
29 Mar 2025
This is a major setback for FDA, improvements in regulatory science, and advancement of innovation for patients! wsj.com/politics/top-vaccine…
1
7
1,497